Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

HOW MISCHIEF AND I HAPPEN TO GO INTO THE COUNTRY.

Autor: OLEMAN, CADDIE C

Publikováno v: Independent (New York, NY 1848-1876); 01/06/1870, Vol. 22 Issue 1101, p5-5, 1/2p

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.

Autor: Parra ER; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Duose DY; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gonzalez-Kozlova E; Department of Oncological Sciences, Mount Sinai, New York, New York.; Tisch Cancer Institute, Mount Sinai, New York, New York.; Precision Immunology Institute, Mount Sinai, New York, New York.; Icahn School of Medicine at Mount Sinai, New York, New York., Redman MW; SWOG Statistical Center, Fred Hutchinson Cancer Center, Seattle, Washington., Chen H; Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Manyam GC; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kumar G; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lazcano R; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Marques-Piubelli ML; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Laberiano-Fernandez C; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rojas F; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang B; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Taing L; CIMAC-CIDC Network, Pipeline Development and Portal Integration, Dana-Farber Cancer Institute, Boston, Massachusetts., Jhaveri A; CIMAC-CIDC Network, Pipeline Development and Portal Integration, Dana-Farber Cancer Institute, Boston, Massachusetts., Geisberg J; CIMAC-CIDC Network, Pipeline Development and Portal Integration, Dana-Farber Cancer Institute, Boston, Massachusetts., Altreuter J; CIMAC-CIDC Network, Pipeline Development and Portal Integration, Dana-Farber Cancer Institute, Boston, Massachusetts., Michor F; CIMAC-CIDC Network, Pipeline Development and Portal Integration, Dana-Farber Cancer Institute, Boston, Massachusetts., Provencher J; CIMAC-CIDC Network, Pipeline Development and Portal Integration, Dana-Farber Cancer Institute, Boston, Massachusetts., Yu J; CIMAC-CIDC Network, Pipeline Development and Portal Integration, Dana-Farber Cancer Institute, Boston, Massachusetts., Cerami E; CIMAC-CIDC Network, Pipeline Development and Portal Integration, Dana-Farber Cancer Institute, Boston, Massachusetts., Moravec R; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Kannan K; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Luthra R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Alatrash G; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer, Houston, Texas., Huang HH; Precision Immunology Institute, Mount Sinai, New York, New York.; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York., Xie H; Precision Immunology Institute, Mount Sinai, New York, New York., Patel M; Precision Immunology Institute, Mount Sinai, New York, New York., Nie K; Precision Immunology Institute, Mount Sinai, New York, New York., Harris J; Precision Immunology Institute, Mount Sinai, New York, New York., Argueta K; Precision Immunology Institute, Mount Sinai, New York, New York., Lindsay J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Biswas R; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Van Nostrand S; CIMAC-CIDC Network, Pipeline Development and Portal Integration, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Kim-Schulze S; Department of Oncological Sciences, Mount Sinai, New York, New York.; Tisch Cancer Institute, Mount Sinai, New York, New York.; Precision Immunology Institute, Mount Sinai, New York, New York.; Icahn School of Medicine at Mount Sinai, New York, New York., Gray JE; Moffitt Cancer Caner, Tampa, Florida., Herbst RS; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Wistuba II; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gettinger S; Moffitt Cancer Caner, Tampa, Florida., Kelly K; International Association for the Study of Lung Cancer, Denver, Colorado., Bazhenova L; University of California San Diego Moores Cancer Center, La Jolla, California., Gnjatic S; Department of Oncological Sciences, Mount Sinai, New York, New York.; Tisch Cancer Institute, Mount Sinai, New York, New York.; Precision Immunology Institute, Mount Sinai, New York, New York.; Icahn School of Medicine at Mount Sinai, New York, New York., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Haymaker C; Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 15; Vol. 30 (8), pp. 1655-1668.

Increasing Medical Student Involvement in Research: Military Ob/Gyn HeadHunters.

Autor: Boedeker D; Department of Gynecologic Surgery and Obstetrics, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA., Chatfield L; Department of Gynecologic Surgery and Obstetrics, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA., Hudson K; Department of Gynecologic Surgery & Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20184, USA., Motoni C; Department of Gynecologic Surgery & Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20184, USA., Kerns N; Department of Obstetrics and Gynecology, Wright State University, OH 45409, Dayton., Lutgendorf M; Department of Gynecologic Surgery & Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20184, USA., Shvartsman K; Department of Gynecologic Surgery & Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20184, USA.

Publikováno v: Military medicine [Mil Med] 2023 Jul 22; Vol. 188 (7-8), pp. e1547-e1551.

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.

Autor: Karam JA; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jakaram@mdanderson.org.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jakaram@mdanderson.org., Msaouel P; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. PMsaouel@mdanderson.org.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PMsaouel@mdanderson.org.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA. PMsaouel@mdanderson.org., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Matin SF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Campbell MT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zurita AJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shah AY; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Marmonti E; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Duose DY; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Soto LMS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Laberiano-Fernandez C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Lozano M; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Abraham A; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Hallin M; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Chin CD; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Olson P, Der-Torossian H; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Yan X; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wood CG; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Publikováno v: Nature communications [Nat Commun] 2023 May 10; Vol. 14 (1), pp. 2684. Date of Electronic Publication: 2023 May 10.